Ovarian Cancer Diagnostics Market to Expand at 7% CAGR Through 2031

Fact.MR – A Market Research and Competitive Intelligence Provider: According to the latest Fact.MR analysis, the global ovarian cancer diagnostics market size was valued at US$ 1.3 Bn in 2020.

Focus on Early Detection Underscoring Ovarian Cancer Diagnostics Market Growth at 7% CAGR

Effectiveness of CA 125 Test to make it a Top-Choice in Ovarian Cancer Diagnostics Market

The Fact.MR report on ovarian cancer diagnostics analyzes trends, opportunities, and threats affecting growth in the market through 2031. It discloses interesting information about strategies adopted by the market players. The study also reveals challenges posing threat to the ovarian cancer diagnostics market. It offers in-depth analysis of the market in terms of cancer type, test type, and end user.

Fact.MR – A Market Research and Competitive Intelligence Provider: According to the latest Fact.MR analysis, the global ovarian cancer diagnostics market size was valued at US$ 1.3 Bn in 2020. With rising incidence of ovarian cancer and increasing emphasis on early diagnosis, the overall market is projected to expand at a strong CAGR of 7% between 2021 and 2031

Medical researchers have revealed that ovarian cancer often goes undetected until it has spread within pelvis and stomach. At this stage, it is more difficult to treat and can thus prove fatal. Hence, demand for ovarian cancer diagnostics is increasing to ensure better accuracy in diagnosis and facilitate prompt treatment.

According to the World Cancer Research Fund (WCRF) and American Institution for Cancer Research, ovarian cancer was the eighth most occurring cancer in women and 18th most commonly occurring cancer overall in 2018. There were nearly 300,000 new cases of ovarian cancer reported in 2018.

Early diagnosis of ovarian cancer can help in reducing the mortality rate in women. When identified early, ovarian cancer is more likely to respond to treatment and can thus result in a greater probability of survival. As a result, more women are frequently opting for ovarian cancer diagnostic tests to monitor their health.

Request a report sample to gain compressive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=51

Governments across the world are launching various initiatives to educate people about ovarian cancer and benefits of its early detection. Also, increasing expenditure and investment on ovarian cancer research activities to develop effective methods for early detection will positively impact the growth in the market.

Currently, CA 125 test for ovarian cancer diagnostics is dominating the global market. It is the most widely used tumor marker. CA-125 is a high molecular weight glycoprotein which is raised in approximately 90% of patients with advanced epithelial ovarian cancer. Various studies have confirmed the usefulness of CA125 in monitoring the progress of patients with epithelial ovarian cancer.

Regionally, North America is expected to dominate the ovarian cancer diagnostics market with a healthy market share. Growing cases of ovarian cancer and presence of leading market players in countries such as the U.S are some of the factors propelling growth in North America market.

According to the American Cancer Society, ovarian cancer is the fifth most common cause of cancer related death among women in the U.S. It estimates that about 21,410 women will receive a new diagnosis of ovarian cancer while about 13,770 women will die from ovarian cancer in 2021.

“Key players operating in the ovarian cancer diagnostics market are focusing on developing new testing methods that could detect the ovarian cancer in its early stages. This, in turn, is expected to accelerate the growth of the market,” says the Fact.MR analyst.

Key Takeaways from Ovarian Cancer Diagnostics Market Survey

  • North America will continue to dominate the ovarian cancer diagnostics market, accounting for around 45% share in 2021.
  • Asia Pacific is projected to emerge as the fastest growing market for ovarian cancer diagnostics during the forecast period.
  • With increasing cases of ovarian cancer and growing awareness for the disease, China and India will emerge as the most lucrative markets within APAC region.
  • Based on cancer type, epithelial tumors segment is expected to account for the largest market share through 2031.
  • In terms of end user, hospital associated laboratories segment accounted for the largest revenue share in global market during 2020.

Key Drivers

  • Growing need for early detection of ovarian cancer to reduce mortality rate is expected to bolster the growth in ovarian cancer diagnostics market.
  • Rising geriatric population is positively impacting the market growth as various studies have proven that incidence of ovarian cancer is comparatively in older women.
  • Introduction of advanced devices in diagnostic methods will continue to boost the market during the forecast period.
  • Increasing emphasis on genetic counselling is emerging as one of the major factors favoring the penetration of tests such as KRAS mutation, HER 2 and BRCA.

Key Restraints

  • As current diagnostic methods are effective only in detecting spread of ovarian cancer at advanced stages, inability for early detection of the disease is expected to restraint the growth.
  • Lack of awareness and dearth of proper reimbursement plans of ovarian cancer diagnostics across the emerging economies will limit the growth in the market.

Ask Your Ovarian Cancer Diagnostics Market Related Questions & Get Customized Reports

https://www.factmr.com/connectus/sample?flag=RC&rep_id=51

Competitive Landscape

  • Key companies operating in the ovarian cancer diagnostics market are investing heavily in research and development activities to develop better diagnostic devices. In March 2021, Roche Holding signed a definitive merger agreement with GenMark Diagnostics, Inc., to test for broad range of pathogen with one patient sample. Acquiring of GenMark Diagnostics will broaden Roche’s molecular diagnostics portfolio to include solutions that can provide lifesaving information quickly to patients and their healthcare providers in the fight against diseases.
  • In September 2019, Inex Innovate announced that it will launch new molecular tests for ovarian cancer and breast cancer in Asia. The new tests will be effective in early diagnosis of these cancer types.

Some of the prominent players operating in the ovarian cancer diagnostics market profiled by Fact.MR are:

  • Abbott Laboratories
  • Roche Holding A.G.
  • Thermo Fisher Scientific Inc.
  • Laboratory Corporation of America Holdings
  • Luminex Corporation
  • Myriad Genetics Inc.
  • Others

More Insights on the Global Ovarian Cancer Diagnostics Sales Outlook

Fact.MR provides an unbiased analysis of ovarian cancer diagnostics market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand for ovarian cancer diagnostics with a detailed segmentation on the basis of:

Cancer Type:

  • Epithelial Tumor Diagnostics
  • Germ Cell Carcinoma Tumor Diagnostics
  • Stromal Carcinoma Tumor Diagnostics

Test Type:

  • CA 125 Test for Ovarian Cancer Diagnostics
  • HER 2 Test for Ovarian Cancer Diagnostics
  • BRCA Test for Ovarian Cancer Diagnostics
  • CEA Test for Ovarian Cancer Diagnostics
  • ER & PR Test for Ovarian Cancer Diagnostics
  • KRAS Mutation Test for Ovarian Cancer Diagnostics
  • Others

End User:

  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Others

Key Questions Covered in the Ovarian Cancer Diagnostics Sales Outlook Report

  • The report offers insight into ovarian cancer diagnostics demand outlook for 2021-2031
  • The market study also highlights projected sales growth for ovarian cancer diagnostics market between 2021 and 2031
  • Ovarian cancer diagnostics market survey identifies key growth drivers, restraints, and other forces impacting prevailing trends and evaluation of current market size and forecast and technological advancements within the industry
  • Ovarian cancer diagnostics market share analysis of the key companies within the industry and coverage of strategies such as mergers & acquisitions, joint ventures, collaborations or partnerships, and others

Explore Fact.MR’s Coverage on the Healthcare Domain –

CTC Diagnostics Market- Circulating tumor cells (CTCs) are a popular topic in cancer research, diagnosis, and treatment these days, as their ability to self-renew is one of the fundamental causes of carcinogenesis. Because of their accuracy and dependability in diagnosing cancer risks and monitoring various cancer treatments, CTC diagnostic tests are becoming increasingly used. In addition, an increasing number of end users, such as hospitals, diagnostic centers, research and academic institutes, and oncology labs, are seeking to engage with manufacturers in the CTC diagnostics field. The remarkable rise of the global circulating tumor cells market is being fueled by this.

Cancer Biomarkers Market- The rising global incidence of cancer and higher adoption of cancer therapies in developing countries, the shift in healthcare from illness diagnosis to risk assessment or early diagnosis, and the increased use of biomarkers in drug development are all driving the global cancer biomarkers market. The paradigm shift toward personalized medicine for cancer therapy due to the lack of conventional diagnosis and treatment is projected to drive up demand for cancer biomarkers. Biomarkers are also becoming more important in personalized medicine, with applications in diagnosis, prognosis, and the selection of targeted therapy.

Cancer Therapeutics Market- Stakeholders in the cancer therapeutics market are increasing research into novel delivery approaches in cancer care, such as integrating peptide vaccines, peptide-based pharmaceuticals, peptide-based therapies, and peptide-conjugated nanomaterials, to provide unique and more efficient cancer treatments. A new window of opportunity for peptide-based medications and peptide-based therapies in the cancer therapeutics industry is projected to open as a result of current research and clinical studies in tailored medicines for battling cancer.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000’s trust us in critical decision making.

MarketNgage is powered by Fact.MR – our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.

You can access all our healthcare research reports by signing up with MarketNgage’s Market Research Subscription with FREE credits. MarketNgage is powered by Fact.MR – A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.

Contact:

Mahendra Singh
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com

Source: Fact.MR